MEET THE TEAM : EARLY STAGE RESEARCHERS
Alessandro Colombano
ESR1
Host Institution:
University of Aberdeen, UK
Project:
WP4 ‘Fatty acid analogues and CPT1 inhibitors as PET tracers for cardiac dysfunction’
Main Supervisor:
Professor Matteo Zanda
Secondment:
6 months at AstraZeneca, Sweden (month 21)
Secondment Supervisor:
Dr Charles Elmore
Ilaria Patruno
ESR2
Host Institution:
University of Aberdeen, UK
Project:
WP4 ‘Development of new derivatives of Fenretinide to support development of drug candidate to treat metabolic syndrome and cancer using PET imaging’
Main Supervisor:
Professor Matteo Zanda
Secondment:
3 months at STICHTING VU, AMS, (month 24)
Secondment Supervisor:
Professor Bert Windhorst
Antonia Hognasbacka
ESR3
Host Institution:
STICHTING VU, Amsterdam, The Netherlands
Project:
WP1 ‘Small-molecule tyrosine kinase inhibitors (TKI) PET in oncology and neurology’
Main Supervisor:
Prof. Bert Windhorst (STICHTING VU)
Secondment:
6 months at Imanova, UK, (month 21)
Secondment Supervisor:
Dr Jan Passchier
Marion Chomet
ESR4
Host Institution:
STICHTING VU, Amsterdam, The Netherlands
Project:
WP1 ‘Reverse translational of Immuno-PET in oncology.’
Main Supervisor:
Professor Bert Windhorst
Secondments:
6 months at University of Aberdeen, UK (month 26)
2 months at Vrije Universiteit Brussel BRU Belgium, (month 33)
Secondment Supervisors:
Professor Matteo Zanda (ABD)
Professor Vicky Caveliers (BRU)
Nuno Da Silva Rosa
ESR5
Host Institution:
VRIJE UNIVERSITEIT BRUSSEL BRU Belgium
Project:
WP2 ‘Development of [18F]-FDR-nanobodies for clinical translation.’
Main Supervisor:
Professor Vicky Caveliers
Secondments:
4 months at University of Aberdeen, UK (month 15)
6 months at Imanova, UK, (month 24)
Secondment Supervisors:
Professor Matteo Zanda (ABD)
Dr Jan Passchier (IMA)
Jessica Bridoux
ESR6
Host Institution:
VRIJE UNIVERSITEIT BRUSSEL BRU Belgium
Project:
WP2 ‘Site-specific nanobody functionalisation as PET imaging and therapy –theranostic tool’
Main Supervisor:
Professor Vicky Caveliers
Secondment:
6 months at AstraZeneca, Sweden (month 26)
Secondment Supervisor:
Dr Charles Elmore
Irene Feiner
ESR7
Host Institution:
Asociacion CIC biomaGUNE, San Sebastian, Spain
Project:
WP3 ‘Synthesis and preclinical investigation of boron-enriched gold nanoparticles: a pre-targeting approach to boron neutron capture therapy.’
Main Supervisor:
Dr Jordi Llop
Secondments:
6 months at University of Aberdeen, UK (month 16)
4 months at IMANOVA, UK (month 29)
Secondment Supervisors:
Professor Matteo Zanda (ABD)
Dr Jan Passchier (IMA)
Rossana Passannante
ESR8
Host Institution:
Asociacion CIC biomaGUNE, San Sebastian, Spain
Project:
WP1 ‘Development of labelling strategies for the incorporation of positron emitters into new chemical entities and evaluate their biodistribution and metabolism: for oncology PET imaging’
Main Supervisor:
Dr Jordi Llop
Secondments:
2 months at Vrije Universiteit, Brussel, Belgium (month 16)
6 months at AstraZeneca, Sweden, (month 28)
Secondment Supervisors:
Professor Vicky Caveliers (BRU)
Dr Chad Elmore (AZ)
Francesco Angelucci
ESR9
Host Institution:
University of Bergen, Norway
Project:
WP1 ‘Novel probes for hypoxia and NTR-reporter gene imaging.’
Main Supervisor:
Professor Hans-René Bjørsvik
Secondment:
6 months at AstraZeneca, Sweden (month 18)
Secondment Supervisor:
Dr Charles Elmore
Davide Cirillo
ESR10
Host Institution:
University of Bergen, Norway
Project:
WP5 ‘Design and development of synthesis strategies leading to booster/targeting molecules that act as radiosensitizers in the frame of cancer therapy’
Main Supervisor:
Professor Hans-René Bjørsvik
Secondment:
6 months at Imanova, UK (month 29)
Secondment Supervisor:
Dr Jan Passchier
Cristina Barca
ESR11
Host Institution:
Westfaelische Wilhelms Universitaet Muenster, Germany
Project:
WP5 ‘Multimodal and multi-tracer imaging of inflammation in stroke’
Main Supervisor:
Professor Andreas Jacobs
Secondment:
6 months at Asociacion CIC biomaGUNE, San Sebastian, Spain (month 15)
Secondment Supervisor:
Dr Jordi Llop
Claudia Foray
ESR12
Host Institution:
Westfaelische Wilhelms Universitaet Muenster, Germany
Project:
WP5 ‘Multimodal two-photon microscopy and PET/MR imaging of glioma growth & angiogenesis’
Main Supervisor:
Professor Andreas Jacobs
Secondment:
6 months at AstraZeneca, Sweden (month 17)
Secondment Supervisor:
Dr Chad Elmore
Beatrice Longo
ESR13
Host Institution:
University of Aberdeen, UK
Project:
WP3 ‘Click pre-targeted PET imaging of disease targeting antibodies.’
Main Supervisor:
Professor Matteo Zanda
Secondment:
6 months at STICHTING VU, AMS, The Netherlands (month 25)
Secondment Supervisor:
Professor Bert Windhorst
Cinzia Marceddu
ESR14
Host Institution:
Imanova Ltd, UK
Project:
Project: WP3 ‘Development of pre-targeting as platform technology for biomolecule labelling.’
Main Supervisor:
Dr Jan Passchier
Secondments:
3 months at University of Bergen, Norway (month 22)
3 months at WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTER, Germany (month 27)
2 months each at ICL, (month 8) and (month 20)
Secondment Supervisors:
Professor Hans-Rene Bjorsvik (BER)
Professor Andreas Jacobs (MUN)
Markus Artlesmair
ESR15
Host Institution:
AstraZeneca plc, Sweden
Project:
Project: WP4 ‘Development of a radioligand and PET ligand for the MC4 receptor.’
Main Supervisor:
Dr Charles Elmore
Secondment:
6 months, University of Aberdeen (Month 24)
Secondment Supervisor:
Professor Matteo Zanda
–
ESR PROJECTS
ESR1
‘Fatty acid analogues and CPT1 inhibitors as PET tracers for cardiac dysfunction.’
Host: ABD
ESR2
ESR2 ‘Development of new derivatives of Fenretinide to support development of drug candidate to treat metabolic syndrome and cancer using PET imaging’
Host: ABD
ESR3
‘Small-molecule tyrosine kinase inhibitors (TKI) PET in oncology and neurology’.
Host: AMS
ESR4
‘Reverse translational of Immuno-PET in oncology.’
Host: AMS
ESR5
‘Development of [18F]-FDR-nanobodies for clinical translation.’
Host: BRU
ESR6
‘Site-specific nanobody functionalization as PET imaging and therapy –theranostic tool.’
Host: BRU
ESR7
‘Synthesis and preclinical investigation of boron-enriched gold nanoparticles: a pre-targeting approach to boron neutron capture therapy.’
Host: SAN
ESR8
‘Development of labelling strategies for the incorporation of positron emitters into new chemical entities and evaluate their biodistribution and metabolism: for oncology PET imaging.’
Host: SAN
ESR9
‘Novel probes for hypoxia and NTR-reporter gene imaging.’
Host: BER
ESR10
‘Design and development of synthesis strategies leading to booster/targeting molecules that act as radiosensitizers in the frame of cancer therapy’
Host: BER
ESR11
‘Multi-modal and multi-tracer imaging of inflammation in stroke’
Host: MUN
ESR12
‘Multimodal two-photon microscopy and PET/MR imaging of glioma growth & angiogenesis.’
Host: MUN
ESR13
‘Click pre-targeted PET imaging of disease targeting antibodies.’
Host: ABD
ESR14
‘Development of pre-targeting as platform technology for biomolecule labelling’
Host: IMA
ESR15
‘Development of a radioligand and PET ligand for the MC4 receptor.’
Host: AZ
–
ESR SUPERVISION
Each of the ESRs recruited by PET3D are assigned:
- A main supervisor, the Beneficiary Scientist in Charge.
- A co-supervisor in the same Institution.
- An advisor at a different Institution, who periodically monitors the activity and progress of the ESRs research and training.
- Secondment supervisor, the Scientist in Charge at the incoming institution will temporarily assume the role of supervisor, whereas the outgoing institution will maintain a close contact with the seconded ESR and will continue to monitor his/her activity by different means (tele/web-conferences, emails, etc. involving both ESR and local supervisors) in order to confirm that the research and training activities are developing in line with the programs.
Importance of non-academic contribution to the supervision
Non-academic contribution to ESRs supervision plays a pivotal role in PET3D. All 13 ESRs recruited by academic participants will spend six months of secondment at one of the two industrial non-academic sites, whereas 2 ESRs recruited directly by the industry beneficiaries IMA and AZ will spend 6 months of secondment at one or more academic sites.
Each ESR will design their Personal Career Development Plan (PCDP) with their host supervisor, then PCDPs will be discussed with co-supervisor and advisor, and finally agreed with the Supervisory Board.
–
ESR ELIGIBILITY & MOBILITY
Eligibility requirements for an Early Stage Researcher under the European Commission Horizon 2020 Early Stage Training Scheme:
To be eligible to be appointed as an Early Stage Researcher:
- On appointment all ESRs will have than four years research experience and will not possess a PhD. This 4 year period is measured from the date of obtaining the degree which would formally entitle to embark on a doctorate.
- On appointment all ESRs must not have resided or carried out their main activity (work, studies, etc.) in the country of appointment for more than twelve months in the three years immediately prior to your recruitment.
–
Mobility
In addition to salary, a mobility allowance is paid to all ESRs
Mobility is required to ensure that all students:
- Have the opportunity to experience a research activity (chemistry, radiochemistry, pharmacology, physics, informatics, biology and medicine) in departments of excellence;
- Follow network-wide multidisciplinary training activities at the general network training events/schools;
- Acquire complementary Pharma-skills, not provided by the home/host beneficiary, at another beneficiary institution;
A minimum of one secondment is planned for each ESR